Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pre-Amyloidosis Red-Flag Clinical Diagnoses in Light Chain (AL) Versus Age-Related Transthyretin (ATTRwt) Amyloidosis: Electronic Health Record-Based Descriptive Study.

JMIR medical informatics·2026
Same author

Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma.

HemaSphere·2026
Same author

Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma.

Science translational medicine·2026
Same author

Secondary Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia Following Prolonged Lenalidomide Maintenance in Multiple Myeloma.

Journal of medical cases·2026
Same author

Effect of insurance status on mortality following surgical treatment of colorectal cancers in the United States.

Scientific reports·2026
Same author

Myelodysplastic Syndrome Secondary to Chimeric Antigen Receptor T-cell (CAR-T) Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma.

Cureus·2026

Related Experiment Video

Updated: Jun 29, 2026

Colony Forming Cell (CFC) Assay for Human Hematopoietic Cells
11:30

Colony Forming Cell (CFC) Assay for Human Hematopoietic Cells

Published on: December 18, 2010

Granulocyte colony-stimulating factor administration: adverse events.

Anita D'Souza1, Ishmael Jaiyesimi, Lance Trainor

  • 1Department of Internal Medicine, William Beaumont Hospital, Royal Oak, MI 48073, USA. anita.dsouza@beaumont.edu

Transfusion Medicine Reviews
|October 14, 2008
PubMed
Summary

Recombinant human granulocyte colony-stimulating factor (G-CSF) is widely used in medicine. This review details the known side effects of G-CSF, highlighting safety considerations for its growing clinical applications.

More Related Videos

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Related Experiment Videos

Last Updated: Jun 29, 2026

Colony Forming Cell (CFC) Assay for Human Hematopoietic Cells
11:30

Colony Forming Cell (CFC) Assay for Human Hematopoietic Cells

Published on: December 18, 2010

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Area of Science:

  • Hematology
  • Pharmacology
  • Immunology

Background:

  • Recombinant human granulocyte colony-stimulating factor (G-CSF) has been clinically utilized for about 20 years.
  • G-CSF is employed in healthy donors for progenitor cell mobilization and in patients to manage neutropenia.
  • Its therapeutic applications are expanding, leading to increased recognition of associated adverse events.

Purpose of the Study:

  • To conduct a comprehensive review of adverse events reported with G-CSF use.
  • To consolidate information on the safety profile of G-CSF across various clinical settings.

Main Methods:

  • Literature review of reported adverse events associated with G-CSF.
  • Analysis of clinical data and published studies on G-CSF side effects.

Main Results:

  • G-CSF is generally considered safe but has recognized side effects.
  • Adverse events vary depending on patient population and clinical indication.
  • Detailed understanding of side effects is crucial given its expanding use.

Conclusions:

  • While G-CSF offers significant therapeutic benefits, a thorough understanding of its adverse event profile is essential.
  • Ongoing monitoring and reporting of side effects will refine G-CSF safety guidelines.
  • This review provides a critical resource for clinicians managing patients receiving G-CSF therapy.